Drug Trial Radar · NCT06961786
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma
Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
9
Planned (sponsor's estimate)
Start
Jun 25, 2025
Primary completion
Nov 2026
Study completion Apr 2027
Sponsor
- Lead sponsor
- TILT Biotherapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.
Conditions
- Metastatic Melanoma
Interventions
TILT-123Biological
TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
TILBiological
Adoptive T cell therapy with TILs
CyclophosphamideDrug
Lymphocyte-depleting chemotherapy
FludarabineDrug
Lymphocyte-depleting chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with any (serious and non-serious) Adverse EventsTime frame: 78 days
- Number of Participants with abnormal laboratory valuesTime frame: 78 days
- Number of Participants with vital sign abnormalitiesTime frame: 78 days
- Safety assessed by 12- lead electrocardiograms (ECGs) Adverse EventsTime frame: 78 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.